Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents - Takeaways - MDSpire

Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents

  • By

  • Marwa Helal

  • Marwa Gamal

  • Ashraf A. Basuni

  • Walaa El Gendy

  • Ashraf Khalil

  • February 23, 2026

  • 0 min

Share

  • 1

    Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, primarily linked to chronic HCV infection.

  • 2

    Telomere length dynamics are crucial in HCC, with telomere shortening contributing to chromosomal instability and cancer progression.

  • 3

    Direct-acting antiviral agents (DAA) have improved HCV treatment outcomes, but their long-term effects on HCC risk require further investigation.

  • 4

    This study compares telomere length in HCC patients with chronic HCV, focusing on differences between DAA-treated and treatment-naïve groups.

  • 5

    Telomere length may serve as a prognostic biomarker for HCC development, influenced by treatment history and chronic inflammation.

Original Source(s)

Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents

  • by Marwa Helal, Marwa Gamal, Ashraf A. Basuni, Walaa El Gendy, Ashraf Khalil

  • February 23, 2026

Related Content

Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids

Development and validation of a deep learning model for liver shear stiffness regression using abdominal multiparametric MRI across multiple sites and vendors

The role of mitochondrial dynamics in metabolic dysfunction–associated steatotic liver disease